Abstract:To evaluate the safety and efficacy of adjuvant radiotherapy after endoscopic resection for stage I esophageal carcinoma with high risk factors. A pilot study of adjuvant radiotherapy for endoscopically resected pT1 esophageal carcinoma was carried out in our single institution. The main inclusion criteria included: (1) Histologically proven thoracic esophageal carcinoma; (2) Clinical staging T1N0M0 patients; (3) pT1 stage with high risk factors (submucosal or lymphovascular invasion) based on endoscopically resected specimen. Enrolled patients received radiotherapy, with or without concurrent chemotherapy. The total radiation dose was 50-60 Gy in 25-30 fractions. The common acute toxicities, dysphagia at last follow-up, local control rate (LCR), overall survival (OS), disease free survival (DFS) and failure pattern were analyzed. From July 2011 to April 2019, 31 consecutive patients were enrolled. There were 25 (80.6%) males and six (19.4%) females. The median age was 62 (49-78) years old. Thirty (96.8%) patients were squamous cell carcinoma, and one (3.2%) was adenocarcinoma. The number of patients with tumor of poor, moderate, moderate-poor and high differentiation were 12 (38.7%), 13 (41.9%), 2 (6.5%) and 4 (12.9%), respectively. Fifteen (48.4%) patients were diagnosed with lymphovascular invasion, and 26 (83.9%) were with submucosal invasion with a median invasion depth of 650 (50-1550) μm. All patients received complete endoscopic submucosal dissection. All patients completed adjuvant radiotherapy as schedule, except one received 44 Gy due to refusal. The common acute toxicities included esophagitis (Grade 1-2, 67.7%; Grade 3, 12.9%), radiation pneumonitis (Grade 1, 48.4%), leucopenia (Grade 1-2, 54.8%), and thrombocytopenia (Grade 1-2, 12.9%). No Grade 4-5 acute toxicities were observed. Six patients (19.4%) received chemotherapy concurrently with radiotherapy. No statistically significant difference of acute toxicities was observed between patients who received concurrent chemotherapy or not. The median follow-up time was 19.7 (95% CI, 12.5-26.9) months. At the last follow-up, 28 (90.5%) patients were able to eat regular diet and only one needed liquid diet. The LCR was 100.0%. Relapse was found in three patients, which was all with distant metastasis, including two with synchronous regional lymph node recurrence. The 1-, 3- and 5-year OS were 100.0%, 88.9%, and 74.1%, respectively. And the 1-, 3- and 5-year DFS were 100.0%, 74.1% and 74.1%, respectively. The median OS and DFS were not reached. In univariate analysis, only tumor size was prognostic factor for OS (p = 0.014). No independent prognostic factor was found for OS and DFS. Adjuvant radiotherapy after endoscopic resection is a safe and efficient supplement treatment for stage I esophageal carcinoma with high risk factors. Chemoradiotherapy may be a more reasonable adjuvant treatment based on the failure pattern.

Esophageal perforation during or after conformal radiotherapy for esophageal carcinoma.

Spontaneous acalculous gallbladder perforation in a man secondary to chemotherapy and radiation: A rare case report.

Increased Esophageal Perforation after Combination of Anti-PD-1 Immunotherapy with Radiotherapy for Esophageal Carcinoma.

Risk Factors for Esophageal Fistula in Esophageal Cancer Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis

Surgical management and prognostic factors in esophageal perforation caused by foreign body

Risk Factors Associated with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma

Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma

Risk factors and prognosis for esophageal fistula in patients with esophageal squamous cell carcinoma during radiotherapy

Risk factors of esophageal fistula induced by re-radiotherapy for recurrent esophageal cancer with local primary site

Analysis of the postoperative prognosis of patients with gastric perforation

Prognostic factors for esophageal respiratory fistula in unresectable esophageal squamous cell carcinoma treated with radiotherapy

Prognostication and Optimal Criteria of Circumferential Margin Involvement for Esophageal Cancer after Chemoradiation and Esophagectomy

Prognosis of Postoperative Radiotherapy for Middle Thoracic Esophageal Carcinoma

High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis

Results and Prognostic Factors of 3-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Esophageal Carcinoma

Prognostic Factors in Patients with Thoracic Esophageal Carcinoma Staged Pt1-4An0m0 Undergone Esophagectomy with Three-Field Lymphadenectomy.

Clinical Analysis of Prognostic Factors of Patients with Perforated Gastric Cancers

Diagnosis and Therapy in Esophageal Perforation and the Outcomes

Adjuvant Radiotherapy after Endoscopic Resection for Stage I Esophageal Carcinoma: Results from a Pilot Study

Analysis of factors of radiation pneumonitis with 3D conformal radiotherapy for esophageal cancer patients

Risk Factors of Perforation in Gastric Stromal Tumors During Endoscopic Resection: a Retrospective Case–control Study